In 2005, Altana posted 1.4 bln eur sales for Pantoprazole.
The company -- which is due to hold an extraordinary general meeting on Tuesday Dec 19 -- said in a detailed statement on the internet that it expects sales for the ulcer drug to fall by another 25 pct by 2016.
Altana is to lose its protection patent for Pantoprazole in Europe in 2009. The statement added that Altana's asthma treatments Ciclesonide and Roflumilast (Daxas) are not in a position to reach their full sales potential, previously put at 1 bln eur each.
In addition, Altana said that it may not file an application for approval of Roflumilast as therapy for smokers' cough to European regulators until 2009, following two more clinical studies.
The company announced in September that it would sell its pharmaceutical unit to Nycomed Holding AS for 4.5 bln eur.
source - AFX